Skip to content

Eli Lilly and Company

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile2 entries

  1. 2025

    Indiana sues Eli Lilly over alleged insulin price-fixing

    Lawsuit filed

    Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.

    Company response

    • Denial — Eli Lilly and Company

      In a statement to WFYI, a company spokesperson said Lilly has taken “industry-leading” steps to lower insulin costs, including capping patient out-of-pocket costs at $35 per month and cutting list prices by 70%.
    • Denial — Eli Lilly and Company

      A spokesperson for Eli Lilly and Company said in an email, “These allegations are baseless and should be dismissed, just like cases brought by other local governments have been.
    • Denial — Lilly

      “PDL played no role in developing donanemab, and Lilly did not use any PDL technology in developing donanemab,” Lilly said in an emailed statement.

    Source excerpt

    • Indiana is suing Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical giant of inflating insulin prices through a coordinated pricing scheme involving secret rebates.
    • The lawsuit alleges Lilly conspired with pharmacy benefit managers to artificially inflate the sticker prices of insulin.
    • The lawsuit, filed Dec. 31 in Lake County Superior Court, builds on legal action Rokita took in March 2024 against other drug manufacturers and pharmacy benefit managers over insulin pricing.
  2. 2023

    Eli Lilly and former employee agree to settle whistleblower lawsuit

    Settlement

    Eli Lilly and former employee Amrit Mula agreed to settle a lawsuit in which Mula alleged that she was terminated after raising concerns about manufacturing practices and data falsification involving company drugs. Lilly said the resolution in no way admitted wrongdoing; settlement details were not disclosed in the article.

    Company response

    • Denial — Eli Lilly and Co

      A Lilly spokesperson said the resolution "in no way admits any wrongdoing," and did not comment on details of the settlement.

    Source excerpt

    • The former human resources officer, Amrit Mula, contended in the lawsuit that she repeatedly urged leaders at a New Jersey plant to remedy problems involving several biologic drugs, including
    • Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings.
    • A Lilly spokesperson said the resolution "in no way admits any wrongdoing," and did not comment on details of the settlement.